Acacia Pharma (Group)

https://www.acaciapharma.com

Acacia Pharma is a hospital pharmaceutical group focused on the development and commercialisation of new nausea & vomiting treatments for surgical and cancer patients. The Group has identified important and commercially attractive unmet needs in nausea & vomiting and has discovered two product candidates based on the same active ingredient, amisulpride, to meet those needs. The Group’s lead project, BAREMSIS for post-operative nausea & vomiting (PONV), has generated positive results in Phase 3 clinical studies and an NDA has been accepted for filing by the US FDA for marketing approval. Its sister project, APD403 for chemotherapy induced nausea & vomiting (CINV) has successfully completed one proof-of-concept and one Phase 2 dose-ranging study in patients receiving highly emetogenic chemotherapy. Acacia Pharma is based in Cambridge, UK and its US operations are centred in Indianapolis, IN. *

	Start	2010-10-23 existent
	Today	Acacia Pharma Ltd.
	Industry	Baremsis (APD421)
	Industry 2	APD403 (Acacia Pharma)
	Person	Gilbert, Julian C. (Acacia Pharma Ltd 201309 CEO + Co-Founder)
	Person 2	Soden, Christine (Acacia Pharma 201507– CFO joined 201502 before Celltech-Chiroscience + BTG + Optos + Medeva + Oxagen)

	Region	Harston, Cambridgeshire
	Country	United Kingdom (GB)
	Street	Harston Mill
	City	CB22 7GG Harston, Cambridgeshire
	Tel	+44-1223-875130
		Address record changed: 2020-12-02

Basic data	Employees	A: 1 to 10 (2018-03-02)
	Currency	GBP
	Profit	-6,172,000 (2017-12-31)
	Cash	3,070,000 (2017-12-31)

		* Document for »About Section«:

		Record changed: 2023-07-10